EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Comparative Effectiveness of Chemotherapy Alone Versus Radiotherapy-Based Regimens in Locally Advanced Pancreatic Cancer: A Real-World Multicenter Analysis (PAULA-1)

Alessandra Arcelli, Giuseppe Tarantino, Francesco Cellini iD, Milly Buwenge, Gabriella Macchia iD, Federica Bertini, Alessandra Guido, Francesco Deodato iD, Savino Cilla, Valerio Scotti, Maria Elena Rosetto iD, Igor Djan und 13 weitere

Current Oncology · 10.06.2023 · 30 (6) · 5690-5703

DOI: 10.3390/curroncol30060427 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Current Oncology, online erschienen am 10.06.2023. Verfasst von Alessandra Arcelli und 24 weiteren Autor:innen. Beteiligte Einrichtung: Radiation Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Radiosurgery. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Different options for locally advanced pancreatic cancer (LAPC) are available based on international guidelines: chemotherapy (CHT), chemoradiation (CRT), and stereotactic body radiotherapy (SBRT). However, the role of radiotherapy is debated in LAPC. We retrospectively compared CHT, CRT, and SBRT ± CHT in a real-world setting in terms of overall survival (OS), local control (LC), and distant metastasis-free survival (DMFS). LAPC patients from a multicentric retrospective database were included (2005–2018). Survival curves were calculated using the Kaplan–Meier method. Multivariable Cox analysis was performed to identify predictors of LC, OS, and DMFS. Of the 419 patients included, 71.1% were treated with CRT, 15.5% with CHT, and 13.4% with SBRT. Multivariable analysis showed higher LC rates for CRT (HR: 0.56, 95%CI 0.34–0.92, p = 0.022) or SBRT (HR: 0.27, 95%CI 0.13–0.54, p < 0.001), compared to CHT. CRT (HR: 0.44, 95%CI 0.28–0.70, p < 0.001) and SBRT (HR: 0.40, 95%CI 0.22–0.74, p = 0.003) were predictors of prolonged OS with respect to CHT. No significant differences were recorded in terms of DMFS. In selected patients, the addition of radiotherapy to CHT is still an option to be considered. In patients referred for radiotherapy, CRT can be replaced by SBRT considering its duration, higher LC rate, and OS rate, which are at least comparable to that of CRT.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pancreatic NeoplasmsRadiosurgeryHumansRetrospective StudiesPancreasChemoradiotherapy

Stichwörter der Autor:innen

chemoradiationchemotherapyconventionally fractionated radiotherapypancreatic cancerstereotactic body radiotherapy

Autor:innen und Institutionen

  • Radiation Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy.
  • Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA.
  • Radioterapia Oncologica ed Ematologia, Dipartimento Universitario Diagnostica per Immagini, Università Cattolica del Sacro Cuore, 00168 Rome, Italy.
  • Radioterapia Oncologica ed Ematologia, Dipartimento di Diagnostica per Immagini, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, 00168 Rome, Italy.
  • Radiation Oncology, Department of Medical and Surgical Sciences-DIMEC, University of Bologna, 40138 Bologna, Italy.
  • Radiation Oncology Unit, Gemelli Molise Hospital, Università Cattolica del Sacro Cuore, 86100 Campobasso, Italy.

ORCID-Profile: Francesco Cellini, Gabriella Macchia, Francesco Deodato, Maria Elena Rosetto, Michele Fiore, Liliana Belgioia, Mariacristina Di Marco, Lidia Strigari, Renzo Mazzarotto, Alessio Giuseppe Morganti

Zitieren

APA

Arcelli, A., Tarantino, G., Cellini, F., Buwenge, M., Macchia, G., Bertini, F., Guido, A., Deodato, F., Cilla, S., Scotti, V., Rosetto, M. E., Djan, I., Parisi, S., Mattiucci, G. C., Fiore, M., Bonomo, P., Belgioia, L., Niespolo, R. M., Gabriele, P., …, & Morganti, A. G. (2023). Comparative Effectiveness of Chemotherapy Alone Versus Radiotherapy-Based Regimens in Locally Advanced Pancreatic Cancer: A Real-World Multicenter Analysis (PAULA-1). Current Oncology, 30(6), 5690-5703. https://doi.org/10.3390/curroncol30060427

Vancouver

Arcelli A, Tarantino G, Cellini F, Buwenge M, Macchia G, Bertini F, et al. Comparative Effectiveness of Chemotherapy Alone Versus Radiotherapy-Based Regimens in Locally Advanced Pancreatic Cancer: A Real-World Multicenter Analysis (PAULA-1). Current Oncology. 2023;30(6):5690-5703. doi:10.3390/curroncol30060427

BibTeX
@article{Arcelli2023,
  author = {Arcelli, Alessandra and Tarantino, Giuseppe and Cellini, Francesco and Buwenge, Milly and Macchia, Gabriella and Bertini, Federica and Guido, Alessandra and Deodato, Francesco and Cilla, Savino and Scotti, Valerio and Rosetto, Maria Elena and Djan, Igor and Parisi, Salvatore and Mattiucci, Gian Carlo and Fiore, Michele and Bonomo, Pierluigi and Belgioia, Liliana and Niespolo, Rita Marina and Gabriele, Pietro and Di Marco, Mariacristina and Simoni, Nicola and Ma, Johnny and Strigari, Lidia and Mazzarotto, Renzo and Morganti, Alessio Giuseppe},
  title = {Comparative Effectiveness of Chemotherapy Alone Versus Radiotherapy-Based Regimens in Locally Advanced Pancreatic Cancer: A Real-World Multicenter Analysis (PAULA-1)},
  journal = {Current Oncology},
  year = {2023},
  volume = {30},
  number = {6},
  pages = {5690--5703},
  doi = {10.3390/curroncol30060427}
}
Kostenlos starten →